BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Actinium Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Actinium Pharmaceuticals's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07157514-3053@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:131I-apamistamab: Phase 2/3 readout est. (NCT07157514)
DESCRIPTION:131I-apamistamab\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: 
 Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Tran
 splant in Relapse/Refractory AML\nEstimated primary completion: February 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/131i-apamistamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 57514
URL:https://assetmemo.bio/drug/131i-apamistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
